vs

Side-by-side financial comparison of DSS, INC. (DSS) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.1M, roughly 1.3× DSS, INC.). DSS, INC. runs the higher net margin — -420.6% vs -507.8%, a 87.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -23.8%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 3.2%).

DSS, Inc. is a diversified technology company offering product authentication solutions, secure identification services, blockchain-based innovation, digital asset management tools, and healthcare technology products. It primarily serves North American, Asian, and European markets across consumer goods, financial services, and healthcare core segments.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

DSS vs TSHA — Head-to-Head

Bigger by revenue
TSHA
TSHA
1.3× larger
TSHA
$5.5M
$4.1M
DSS
Growing faster (revenue YoY)
TSHA
TSHA
+195.1% gap
TSHA
171.3%
-23.8%
DSS
Higher net margin
DSS
DSS
87.1% more per $
DSS
-420.6%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
3.2%
DSS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DSS
DSS
TSHA
TSHA
Revenue
$4.1M
$5.5M
Net Profit
$-17.4M
$-27.9M
Gross Margin
Operating Margin
-98.1%
-516.0%
Net Margin
-420.6%
-507.8%
Revenue YoY
-23.8%
171.3%
Net Profit YoY
47.2%
-48.3%
EPS (diluted)
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DSS
DSS
TSHA
TSHA
Q4 25
$4.1M
$5.5M
Q3 25
$6.4M
$0
Q2 25
$5.3M
$2.0M
Q1 25
$5.0M
$2.3M
Q4 24
$5.4M
$2.0M
Q3 24
$5.6M
$1.8M
Q2 24
$4.2M
$1.1M
Q1 24
$3.9M
$3.4M
Net Profit
DSS
DSS
TSHA
TSHA
Q4 25
$-17.4M
$-27.9M
Q3 25
$-2.2M
$-32.7M
Q2 25
$-2.6M
$-26.9M
Q1 25
$-5.3M
$-21.5M
Q4 24
$-32.9M
$-18.8M
Q3 24
$-5.3M
$-25.5M
Q2 24
$-4.7M
$-20.9M
Q1 24
$-4.1M
$-24.1M
Operating Margin
DSS
DSS
TSHA
TSHA
Q4 25
-98.1%
-516.0%
Q3 25
-50.6%
Q2 25
-64.8%
-1347.1%
Q1 25
-75.2%
-930.5%
Q4 24
-522.7%
-985.8%
Q3 24
-83.4%
-1448.4%
Q2 24
-117.2%
-1915.4%
Q1 24
-120.9%
-713.3%
Net Margin
DSS
DSS
TSHA
TSHA
Q4 25
-420.6%
-507.8%
Q3 25
-34.9%
Q2 25
-49.3%
-1353.6%
Q1 25
-106.9%
-935.2%
Q4 24
-606.7%
-929.0%
Q3 24
-94.4%
-1427.5%
Q2 24
-111.2%
-1882.0%
Q1 24
-105.2%
-705.4%
EPS (diluted)
DSS
DSS
TSHA
TSHA
Q4 25
$-0.08
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.08
Q4 24
$-4.64
$-0.07
Q3 24
$-0.75
$-0.10
Q2 24
$-0.66
$-0.09
Q1 24
$-0.58
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DSS
DSS
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$8.9M
$319.8M
Total DebtLower is stronger
$44.7M
Stockholders' EquityBook value
$-832.0K
$246.9M
Total Assets
$67.6M
$343.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DSS
DSS
TSHA
TSHA
Q4 25
$8.9M
$319.8M
Q3 25
$8.7M
$297.3M
Q2 25
$12.4M
$312.8M
Q1 25
$17.3M
$116.6M
Q4 24
$14.3M
$139.0M
Q3 24
$18.9M
$157.7M
Q2 24
$20.3M
$172.7M
Q1 24
$17.7M
$124.0M
Total Debt
DSS
DSS
TSHA
TSHA
Q4 25
$44.7M
Q3 25
$50.2M
Q2 25
$43.9M
Q1 25
$49.3M
Q4 24
$57.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DSS
DSS
TSHA
TSHA
Q4 25
$-832.0K
$246.9M
Q3 25
$14.2M
$219.0M
Q2 25
$15.7M
$248.7M
Q1 25
$17.9M
$55.1M
Q4 24
$19.9M
$71.5M
Q3 24
$52.1M
$88.8M
Q2 24
$55.2M
$108.9M
Q1 24
$59.9M
$53.8M
Total Assets
DSS
DSS
TSHA
TSHA
Q4 25
$67.6M
$343.3M
Q3 25
$92.1M
$316.6M
Q2 25
$93.4M
$333.3M
Q1 25
$92.4M
$138.4M
Q4 24
$106.5M
$160.4M
Q3 24
$142.7M
$180.2M
Q2 24
$144.4M
$200.4M
Q1 24
$148.5M
$153.0M
Debt / Equity
DSS
DSS
TSHA
TSHA
Q4 25
Q3 25
3.54×
Q2 25
2.80×
Q1 25
2.76×
Q4 24
2.87×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DSS
DSS
TSHA
TSHA
Operating Cash FlowLast quarter
$-1.6M
$-26.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DSS
DSS
TSHA
TSHA
Q4 25
$-1.6M
$-26.7M
Q3 25
$-8.0M
$-24.2M
Q2 25
$2.1M
$-20.2M
Q1 25
$-1.6M
$-22.0M
Q4 24
$-2.9M
$-18.3M
Q3 24
$-315.0K
$-21.6M
Q2 24
$-3.4M
$-21.5M
Q1 24
$-2.1M
$-19.8M
Free Cash Flow
DSS
DSS
TSHA
TSHA
Q4 25
Q3 25
$-8.1M
$-24.3M
Q2 25
$2.0M
Q1 25
$-1.7M
Q4 24
$-3.0M
$-18.3M
Q3 24
$-21.6M
Q2 24
$-3.5M
$-21.7M
Q1 24
$-2.2M
$-19.9M
FCF Margin
DSS
DSS
TSHA
TSHA
Q4 25
Q3 25
-126.5%
Q2 25
37.4%
Q1 25
-34.1%
Q4 24
-54.9%
-905.5%
Q3 24
-1210.9%
Q2 24
-81.9%
-1951.9%
Q1 24
-55.6%
-584.5%
Capex Intensity
DSS
DSS
TSHA
TSHA
Q4 25
Q3 25
1.3%
Q2 25
1.7%
Q1 25
1.0%
Q4 24
1.9%
0.1%
Q3 24
0.0%
2.0%
Q2 24
0.6%
18.1%
Q1 24
0.1%
4.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons